MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526337 | Name: Sibrafiban

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sibrafiban is an orally active non-peptide GPIIb/IIIa antagonist, under development by Genentech and Hoffmann-La Roche, and in phase III trials as an antithrombotic.

Chemical Structure

Sibrafiban
Sibrafiban
CAS#170094-62-9

Theoretical Analysis

MedKoo Cat#: 526337

Name: Sibrafiban

CAS#: 170094-62-9

Chemical Formula: C20H28N4O6

Exact Mass: 420.2009

Molecular Weight: 420.47

Elemental Analysis: C, 57.13; H, 6.71; N, 13.33; O, 22.83

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Sibrafiban; RO 48-3657/001; RO-48-3657; RO-48-3657/001.
IUPAC/Chemical Name
ethyl (Z)-2-((1-((4-(N'-hydroxycarbamimidoyl)benzoyl)-L-alanyl)piperidin-4-yl)oxy)acetate
InChi Key
WBNUCLPUOSXSNJ-ZDUSSCGKSA-N
InChi Code
InChI=1S/C20H28N4O6/c1-3-29-17(25)12-30-16-8-10-24(11-9-16)20(27)13(2)22-19(26)15-6-4-14(5-7-15)18(21)23-28/h4-7,13,16,28H,3,8-12H2,1-2H3,(H2,21,23)(H,22,26)/t13-/m0/s1
SMILES Code
CCOC(=O)COC1CCN(CC1)C(=O)[C@H](C)NC(=O)c2ccc(cc2)/C(=N/O)/N
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 420.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wong CK, Newby LK, Bhapker MV, Aylward PE, Pfisterer M, Alexander KP, Armstrong PW, Hochman JS, Van de Werf F, Califf RM, White HD; SYMPHONY and 2nd SYMPHONY Investigators.. Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. Am Heart J. 2007 Aug;154(2):313-21. PubMed PMID: 17643582. 2: Frazier CG, Shah SH, Armstrong PW, Bhapkar MV, McGuire DK, Sadowski Z, Kristinsson A, Aylward PE, Klein WW, Weaver WD, Newby LK; SYMPHONY and the Second SYMPHONY Investigators.. Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials. Am Heart J. 2005 Dec;150(6):1260-7. PubMed PMID: 16338269. 3: Feldstein CA. Sibrafiban (Genentech). IDrugs. 1999 May;2(5):460-5. PubMed PMID: 16155849. 4: Second SYMPHONY Investigators.. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation. 2001 Apr 3;103(13):1727-33. PubMed PMID: 11282902. 5: Reimann JD, Modi NB, Novotny W. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin. J Clin Pharmacol. 2000 May;40(5):488-95. PubMed PMID: 10806602. 6: Wittke B, Ensor H, Chung J, Birnböck H, Lausecker B, Ertel SI, MacKie IJ, Machin SJ. Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. Br J Clin Pharmacol. 2000 Mar;49(3):231-9. PubMed PMID: 10718778; PubMed Central PMCID: PMC2014917. 7: Timm U, Birnböck H, Erdin R, Hopfgartner G, Zumbrunnen R. Determination of the oral platelet aggregation inhibitor Sibrafiban in rat, dog, and human plasma utilising HPLC-column switching combined with turbo ion spray single quadrupole mass spectrometry. J Pharm Biomed Anal. 1999 Oct;21(1):151-63. PubMed PMID: 10701922. 8: Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet. 2000 Jan 29;355(9201):337-45. PubMed PMID: 10665552. 9: Sibrafiban. RO 483657, RO 483657-000, Xubix. Drugs R D. 1999 May;1(5):387-9. PubMed PMID: 10566072. 10: Newby LK. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee. Am Heart J. 1999 Aug;138(2 Pt 1):210-8. PubMed PMID: 10426831. 11: Modi NB, Novotny W, Reimann JD, Cannon CP, Braunwauld E. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome. J Clin Pharmacol. 1999 Jul;39(7):675-84. PubMed PMID: 10392322. 12: Wittke B, Mackie IJ, Machin SJ, Timm U, Zell M, Goggin T. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers. Br J Clin Pharmacol. 1999 May;47(5):521-30. PubMed PMID: 10336576; PubMed Central PMCID: PMC2014180. 13: Dooley M, Goa KL. Sibrafiban. Drugs. 1999 Feb;57(2):225-30; discussion 231-2. Review. PubMed PMID: 10188763. 14: Modi NB, Lin YS, Reynolds T, Shaheen A, Christian BJ. Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles. J Cardiovasc Pharmacol. 1998 Sep;32(3):397-405. PubMed PMID: 9733353. 15: Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation. 1998 Feb 3;97(4):340-9. PubMed PMID: 9468207.